Keros Therapeutics, Inc.
KROS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $0 | $0 | $20 |
| % Growth | 2,251% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $0 | $0 | $20 |
| % Margin | 100% | 100% | – | 100% |
| R&D Expenses | $174 | $135 | $87 | $55 |
| G&A Expenses | $41 | $35 | $28 | $21 |
| SG&A Expenses | $41 | $35 | $28 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $214 | $170 | $115 | $76 |
| Operating Income | -$211 | -$170 | -$115 | -$56 |
| % Margin | -5,939% | -112,543.7% | – | -280.5% |
| Other Income/Exp. Net | $24 | $17 | $10 | -$0 |
| Pre-Tax Income | -$187 | -$153 | -$105 | -$57 |
| Tax Expense | $0 | $0 | $0 | $2 |
| Net Income | -$187 | -$153 | -$105 | -$59 |
| % Margin | -5,277.5% | -101,319.2% | – | -292.3% |
| EPS | -5 | -5.2 | -4.15 | -2.52 |
| % Growth | 3.8% | -25.3% | -64.7% | – |
| EPS Diluted | -5 | -5.2 | -4.15 | -2.52 |
| Weighted Avg Shares Out | 37 | 29 | 25 | 23 |
| Weighted Avg Shares Out Dil | 37 | 29 | 25 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$186 | -$152 | -$104 | -$56 |
| % Margin | -5,234.5% | -100,779.5% | – | -280.4% |